daytrading nov 18 morning, page-126

It's interesting that biotechs can hold onto market sensitive news. PAB's 4th cohort was dosed a couple of months ago. At day 29 and day 32 the patients have blood tests which show whether the drug is working or not. If it is working, they get another dosage. Then they get tested again at 60 days, the trial ends, and the data is collated and analysed. So, I'm guessing it does show efficacy because Onyx wanted to test it with their drug... but we don't really know.